Which adjuvant treatments and what are their indications following resection for cure in colonic cancer?;Quels sont les traitements adjuvants et leurs indications apres exerese curative des cancers du colon?

Gastroenterologie Clinique et Biologique

Volumn 22, Issue 3 BIS, 1998, Pages

  Rougier, Philippe ^a   Seitz, Jean François ^b  

^a HÔPITAL AMBROISE PARÉ   (France)

^b INSTITUT PAOLI CALMETTES   (France)

Author keywords

Adjuvant treatment; Chemotherapy; Colonic cancer; Immunotherapy; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; LEVAMISOLE; LOMUSTINE; MITOMYCIN C; SEMUSTINE; VINCRISTINE SULFATE;

CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; COLON CANCER; CONFERENCE PAPER; HUMAN; TREATMENT INDICATION;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT;

EID: 0031864667     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (89)

1. Mayer RJ, O'Connell MJ, Tepper JE, Wolmark N. Status of adjuvant therapy for colorectal cancer. J Natl Cancer Inst 1989;81:1359-64.
2. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA. The intergroup study of fluorouracil (5-FU) plus levamisole (lev) and levamisole alone as adjuvant therapy for stage C colon cancer. A final report. Proc Am Soc Clin Oncol 1992;11:161.
3. Seitz JF, Rougier P. Efficacité de la chimiothérapie dans les cancers du colon. Bull Cancer (Paris) 1994;81:260-76.
4. Bécouam Y, Seitz JF, Perrier H, Rouhier ML, Giovannini M, Brunet R. Immunotherapy of colorectal cancers. Gastroenterol Clin Biol 1996;20:20-32.
5. Buyse M, Zeleniuch Jacquotte A, Chalmers TC. Adjuvant therapy of colorectal cancer. Why we still don't know. JAMA 1988;259:3571-8.
6. Zalcberg JR, Siderov J, Simes J. The role of 5-fluorouracil dose in the adjuvant therapy of colorectal cancer. Ann Oncol 1996;7:41-6.
7. Nakazato H, Koike A, Sail S, Suzuki H, Takagi H, Nimura A, et al. Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer: a prospective randomized clinical trial (abstract). Proc Am Soc Clin Oncol 1997;16:279a.
8. Sakamoto J, Hamada C, Kodaira S, Nakazato H, Ohashi Y. A meta-analysis of adjuvant therapy using oral fluoropyrimydines in patients with curatively resected colorectal carcinoma (abstract). Proc Am Soc Clin Oncol 1997;16:266a.
9. Wolmark N, Fisher B, Rockette H, Redmond C, Wickerham DL, Fisher ER, et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst 1988;80:30-6.
10. Boice JD Jr, Greene MH, Killen JY Jr, Ellenberg SS, Keehn RJ, McFadden E, et al. Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU). N Engl J Med 1983;309:1079-84.
11. The Colorectal Cancer Chemotherapy Study Group of Japan. Five-year results of a randomized controlled trial of adjuvant chemotherapy for curative resected colorectal carcinoma. Jpn J Clin Oncol 1995;25:91-103.
12. Ross P, Norman D, Cunningham D, Webb A, Iveson T, Padhani A, et al. A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol 1997;8:995-1001.
13. Cicera L, Balil A, Batiste E, Tusquets I, Cardona T, Arcusa A, et al. Efficacy of adjuvant mitomycinC plus tegafur in stage III gastric cancer (abstract). Proc Am Soc Clin Oncol 1997;16:278a.
14. Windle R, Bell PR, Shaw D. Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer. Br J Surg 1987;74:569-72.
15. Laurie JA, Moertel CG, Fleming TR, Wieand HS, Leigh JE, Rubin J, et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 1989;7:1447-56.
16. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma, N Engl J Med 1990;322:352-8.
17. Bedikian AY, Valdivieso M, Mavligit GM, Burgess MA, Rodriguez V, Bodey GP. sequential chemoimmunotherapy of colorectal cancer. Evaluation of methotrexate, Barker's antifolate and levamisole. Cancer 1978;42:2169-76.
18. Borden EC, Davis TE, Crowley JJ, Terry WD, Rosenberg SA. Interim analysis of a trial of levamisole and 5-fluorouracil in metastatic colorectal carcinoma. In: Immunotherapy of human cancer. New York: Excerpta Medica; 1982:231-5.
19. Buroker TR, Moertel CG, Fleming TR, Everson LK, Cullinan SA, Krook, et al. A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma. J Clin Oncol 1985;3:1624-31.
20. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laune JA, Tangen, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995;122:321-6.
21. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990;264:1444-50.
22. Luppi G, Zoboli A, Barbieri F, Crisi G, Piccinini L, Silingardi V. On behalf of the INTACC. Multifocal leukoencephalopathy associated with 5-fluorouracil and levamisole adjuvant therapy for colon cancer. A report of two cases and review of the literature. Ann Oncol 1996;7:412-5.
23. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992;10:896-903.
24. Zaniboni A, Elichman C, Seitz JF, Shepherd L, Milan C, Labianca R, et al. FUFA increases disease-free survival (DFS) in resected B2C colon cancer (CC):results of a prospective pooled analysis of 3 randomised trials (RCTs) (abstract). Proc Am Soc Clin Oncol 1993;12:191.
25. IMPACT. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995;345:939-44.
26. Francini G, Petrioli R, Lorenzini L, Mancini S, Armenio S, Tanzini G, et al. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 1994;106:899-906.
27. O'Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Mayer RJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997;15:246-50.
28. Wolmark N, Rockette H, Fisher B, Wickerham DL, Redmond C, Fisher ER, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993;11:1879-87.
29. Haller DG, Catalano PJ, Macdonald JS, Mayer RJ. Fluorouracil (FU), leucovorin (LEV) adjuvant therapy for colon cancer: four-year results of INT-0089 (abstract). Proc Am Soc Clin Oncol 1997;16:265a.
30. O'Connell MJ, Laurie JA, Shepherd L, Kahn MJ, Pazdur R, Fitzgibbons RJ, et al. A prospective evaluation of chemotherapy duration and regimen as surgical adjuvant treatment for high-risk colon cancer: a collaborative trial of the North Central Cancer Treatment Group and the National Cancer Institute of Canada Clinical Trials Group (abstract). Proc Am Soc Clin Oncol 1996;15:209.
31. Wolmark N, Rockette H, Mamounas EP, Jones J, Petrelli N, Atkins J, et al. The relative efficacy of 5-FU + leucovorin (FU-LV), 5-FU + levamisole (FU-LEV), and 5-FU + leucovorin + levamisole (FU-LV-LEV) in patients with Dukes' B and C carcinoma of the colon: first report of NSABP C-04 (abstract). Proc Am Soc Clin Oncol 1996;15:205.
32. Peretz T, Figer A, Borovik R, Steiner M, Catane R, Sulkes A, et al. 5-FU + leucovorin (LV) as active and less toxic regimen than 5-FU + levamisole (LM) in the adjuvant therapy of colorctal cancer - Israel Cooperative Oncology Group (abstract). Proc Am Soc Clin Oncol 1997;16:265a.
33. Mamounas EP, Rockette H, Jones J, Wieand S, Wickerham DL, Fisher B, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B vs Dukes' C colon cancer: results from four NSABP adjuvant studies (C-01, C-02, C-03, C-04) (abstract). Proc Am Soc Clin Oncol 1996;15:205.
34. Erlichman C, Marsoni S, Seitz JF, Skillings J, Shepard L, Zee B, et al. Event free and overall survival is increased by FUFA in resected B colon cancer: a pooled analysis of five randomized trials (RCTS) (abstract). Proc Am Soc Clin Oncol 1997;16:280a.
35. Witzig TE, Loprinzi CL, Gonchoroff NJ, Reiman HM, Cha SS, Wieand HS, et al. DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal adenocarcinoma. Cancer 1991;68:879-88.
36. Jessup JM, Summerhayes IC, Shibata D, Cangi G, Lavin PT, Mercurio AM, et al. Multivariate analysis of tissue-based prognostic markers in stage II-III colorectal carcinoma (abstract). Proc Am Assoc Clin Oncol 1997;16:256a.
37. Danenberg K, Metzger R, Groshen S. Thymidylatc synthase (TS) and thymidine phosphorylase (TP) are prognostic indicators of survival for colorectal cancer (abstract). Proc Am Soc Clin Oncol 1997;16:257a.
38. Elwell A, Xiong YP, Chang M, Leichman CG, Johnston PG, Groshen S, et al. p53, p21 and thymidylate synthase (TS) protein expression: associations with recurrence in stage II and III rectal cancer (abstract). Proc Am Soc Clin Oncol 1997;16:258a.
39. Penna C, Nordlinger B. locoregional chemotherapy for adjuvant treatment of colorectal adenocarcinoma. Eur J Cancer 1996;32A:1117-22.
40. Speyer JL, Sugarbaker PH, Collins JM, Dedrick RL, Klecber RW Jr, Myers Ce. Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer Res 1981;41:1916-22.
41. Nordlinger B, Puts JP, Hervé JP, Delero R, Ballet F. An experimental model of colon cancer: recurrence after surgery alone or associated with intraperitoneal 5-fluorouracil chemotherapy. Dis Colon Rectum 1991;34:658-63.
42. Sugarbaker PH, Gianola FJ, Speyer JL, Wesley R, Barofsky I, Myers CE. Prospective randomized trial of intravenous versus intraperitoneal 5 FU in patients with advanced primary colon or rectal cancer. Semin Oncol 1985;12:101-11.
43. Nordlinger B, Bouteloup PY, Faure JP, Jaeck D, Pellissier E, Grandjean JP, et al. Early post-operative intraperitoneal chemotherapy is feasible and well tolerated in colon cancer. A prospective randomized study. J Cancer Res Clin Oncol 1990;116:686.
44. Scheithauer W, Kornek G, Rosen H, Sebesta C, Marcell A, Kwasny W, et al. Combined intraperitoneal plus intravenous chemotherapy after curative resection for colonic adenocarcinoma. Eur J Cancer 1995;31A:1981-6.
45. Scheithauer W, Marczell A, Depisch D, Salem G, Stöger F, Kornek G, et al. Combined intravenous (IV) and intraperitoneal (IP) chemotherapy with 5-fluorouracil (5-FU) + leucovorin (LV) versus 5-FU + levamisole for adjuvant therapy of resected colon carcinoma (abstract). Proc Am Soc Clin Oncol 1996;15:216.
46. Ramirez LH, Munck JN, Bognel C, Zhao Z, Ardouin P, Poupon MF, et al. Pharmacology and antitumor effects of intraportal pirarubicin on experimental liver metastases. Br J Cancer 1993;68:277-81.
47. Taylor I, Machin D, Mullee M, Trotter G, Cooke T, West C. A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer. Br J Surg 1985;72:359-63.
48. Beart RW Jr, Moertel CG, Wieand HS, Leigh JE, Windschitl HE, Van Heerden JA, et al. Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion. A study of the Mayo Clinic and the North Central Cancer Treatment Group. Arch Surg 1990;125:897-901.
49. Fielding LP, Hittinger R, Grace RH, Fry JS. Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma. Lancet 1992;340:502-6.
50. Gray BN, de Zwart J, Fisher R, Burns I, Hurley R, Isbister W, et al. The Australia and New Zealand trial of adjuvant chemotherapy in colon cancer. In: Salmon SE, ed. Adjuvant therapy of cancer. New York: Grune & Stratton, 1987:537-54.
51. Ryan J, Weiden P, Crowley J, Bloch K. Adjuvant portal vein infusion for colorectal cancer. A 3-arm randomized trial (abstract). Proc Am Soc Clin Oncol 1988;7:95.
52. Sak K. Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer. Swiss Group for Clinical Cancer Research (SAKK). Lancet 1995;345:349-53.
53. Wereldsma JC, Bruggink ED, Meijer WS, Roukema JA, van Putten WL. Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/heparin versus urokinase versus control. Results of a prospective randomized clinical trial (colorectal adenocarcinoma trial I). Cancer 1990;65:425-32.
54. Wolmark N, Rockette H, Petrelli N, Jones J, Redmond C, Fisher B, et al. Long-term results of the efficacy of perioperative portal vein infusion of 5-FU for treatment of colon cancer: NSABP C-02 (abstract). Proc Am Soc Clin Oncol 1994;13:194.
55. Nitti D, Wils J, Sahmoud T, Curran D, Couvreur ML, Lise M, et al. Final results of a phase III clinical trial on adjuvant intraportal infusion with heparin and 5-fluorouracil (5-FU) in resectable colon cancer (EORTC GITCCG 1983-1987). Eur J Cancer 1997;33:1209-15.
56. Sahmoud T, Rougier P, Nitti D, Doci R, De Waele B, Nakajima T, et al. Adjuvant portal vein infusion of 5-FU and heparin (PVI) in colorectal cancer: an EORTC-GIVIO inter-group phase III trial (abstract). Ann Oncol 1996;7:(suppl. 5):33.
57. Gray R, James R, Mossman J, Stenning S. AXIS - a suitable case for treatment. UK Coordinating Committee on Cancer Research (UKCCCR) Colorectal Cancer Subcommittee. Br J Cancer 1991;63:841-5.
58. Rougier P, Sahmoud T, Nitti D, Curran D, Doci R, De Waele B, et al. Adjuvant portal vein infusion of 5-FU and Heparine in colorectal cancer: an intergroup phase III trial. Lancet 1998; (in press).
59. Liver infusion meta-analysis group. Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. J Natl Cancer Inst 1997;89:497-505.
60. Eggermont AMM, Steller EP, Sugarbaker PH. Laparotomy enhances intraperitoneal tumor growth and abrogates the antitumor effects of interleukin-2 and lymphokine-activated killer cells. Surgery 1987;102:71-8.
61. Sedman PC, Ramsden CW, Brennan TG, Giles GR, Guillou PG. Effects of low dose perioperative interferon on the surgically induced suppression of immune responses. Br J Surg 1988;75:976-81.
62. Elias GE, Elias LL, Didolkar MS, Hebel JR. Cellular immunity in patients with colorectal adenocarcinoma measured by autologus leukocyte migration inhibition. Cancer 1977;40:687-92.
63. Elias D. Répercussions de l'acte chirurgical sur la croissance des tumeurs. Ann Chir 1996;44:699-704.
64. Amery WK, Gough GH. Levamisole and immunotherapy: some theoritic and pratical considerations and their relevance to human disease. Oncology 1981;38:168-81.
65. Stevenson HC, Green I, Hamilton JM, Calabro BA, Parkinson DR. Levamisole: known effects on the immune system, clinical results, and future applications to the treatment of cancer. J Clin Oncol 1991;9:2052-66.
66. Arnaud JP, Buyse M, Nordlinger B, Martin F, Pector JC, Zeitoun P, et al. Adjuvant therapy of poor prognosis colon cancer with levamisole: results of an EORTC double-blind randomized clinical trial. Br J Surg 1989;76:284-9.
67. Chlebowski RT, Lillington L, Nystrom JS, Sayre J. Late mortality and levamisole adjuvant therapy in colorectal cancer. Br J Cancer 1994;69:1094-7.
68. Lacour J, Laplanche A, Malafosse M, Gallot D, Julien M, Rotman N, et al. Polyadenylic-polyuridylic acid as an adjuvant in resectable colorectal carcinoma: a 6 1/2 year follow-up analysis of a multicentric double blind randomized trial. Eur J Surg Oncol 1992;18:599-604.
69. Mitomi T, Tsuchiya S, Iijima N, Aso K, Suzuki K, Nishiyama K, et al. Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum (Kanagawa). Dis Colon Rectum 1992;35:123-30.
70. Barkla DH, Tutton PJ. Influence of histamine and serotonin antagonists on the growth of xenografted human colorectal tumors. J Natl Cancer Inst 1981;67:1207-11.
71. Tonnesen H, Knigge U, Bülow S, Damm P, Fisherman K, Esselfeldt P, et al. Effect of cimetidine on survival after gastric cancer. Lancet 1988;1:990-2.
72. Svendsen LB, Ross C, Knigge U, Frederiksen HJ, Graversen P, Kjaergard J, et al. Cimetidine as an adjuvant treatment in colorectal cancer. A double-blind, randomized pilot study. Dis Colon Rectum 1995;38:514-8.
73. Kelly SA, Gschmeissner S, East N, Balkwill FR. Enhancement of metastatic potential by g-interferon. Cancer Res 1991;51:4020-7.
74. Wiesenfeld M, O'Connell MJ, Wieand HS, Gonchoroff NJ, Donohue JH, Fitzgibbons RJ, et al. Controlled clinical trial of interferon-gamma as postoperative surgical adjuvant therapy for colon cancer. J Clin Oncol 1995;13:2324-9.
75. Hoover HC, Jr., Brandhorst JS, Peters LC, Surdyke MG, Takeshita Y, Madariaga J, et al. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol 1993;11:390-9.
76. Harris J, Ryan L, Adams G. Survival and relapse in adjuvant autologous tumor vaccine therapy for Duke B and C colon cancer (abstract). Proc Am Soc Clin Oncol 1994;13:A955.
77. Gray BN, Walker C, Andrewartha L, Freeman S, Bennett RC. Controlled clinical trial of adjuvant immunotherapy with BCG and neuraminidase-treated autologous tumour cells in large bowel cancer. J Surg Oncol 1989;40:34-7.
78. Vermorken JB, Claessen A, Gall H, Van Tinteren H, Meijer S, et al. Randomized phase III trial of active specific immunotherapy (ASI) versus control in patients with Dukes' B2, B3 or C colon cancer (abstract). Eur J Cancer 1997;33:S162.
79. Riethmuller G, Schneider Gadicke E, Schlimok G, Schmiegel W, Raab R, et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet 1994;343:1177-83.
80. Gunderson LL, Sosin H, Levitt S. Extrapelvic colon-areas of failure in a reoperation series: implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 1985;11(4):731-41.
81. Kopelson G. Adjuvant postoperative radiation therapy for colorectal carcinoma above the peritoneal reflection. I. Sigmoid colon. Cancer 1983;51:1593-8.
82. Shehata WM, Meyer RL, Jazy FK, Cormier WJ, Welling RE. Regional adjuvant irradiation for adenocarcinoma of the cecum. Int J Radiat Oncol Biol Phys 1987;13:843-6.
83. Willett CG, Fung CY, Kaufman DS, Efird J, Shellito PC. Postoperative radiation therapy for high-risk colon carcinoma. J Clin Oncol 1993;11:1112-7.
84. Fédération Nationale des Centres de Lutte Contre le Cancer. FNLCC. Standards, Options et Recommandations. Cancers digestifs. Paris: Arnette Blackwell; 1995.
85. De Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997;15:808-15.
86. Zalcberg JR, Cunningham D, Van Cutsem E, Francois E, Schoraagel J, Adenis A, et al. ZD1694: a novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group. J Clin Oncol 1996;14:716-21.
87. Harper P. Advanced colorectal cancer (ACC): results from the latest raltitrexed TomudexR (raltitrexed) comparative study (abstract). Proc Am Soc Clin Oncol 1997;16:228a.
88. Seitz JF, Cunningham D, Rath U, Olver N, Van Cutsem E, Kerr D, et al. Final results and survival data of large randomised trial of « Tomudex » in advanced colorectal cancer (ACC) confirm comparative efficacy to 5-fluorouracil plus leucovorin (5FU + LV) (abstract). Proc Am Soc Clin Oncol 1996;15:201.
89. Pazdur R, Vincent M. Raltitrexed (Tomudex®) versus 5-fluorouracil and leucovorin (5-FU + LV) in patients with advanced colorectal cancer (ACC): results of a randomized, multicenter, North American trial (abstract). Proc Am Soc Clin Oncol 1997;16:228a.